The Lancet Oncology
Fecha de publicación: 21 february 2019
Autores: Prof Mary Beth Terry, PhD., Yuyan Liao, MS., Prof Alice S Whittemore, PhD., Nicole Leoce, DrPH., Richard Buchsbaum., Nur Zeinomar, PhD., et al.
Background: Independent validation is essential to justify use of models of breast cancer risk prediction and inform decisions about prevention options and screening. Few independent validations had been done using cohorts for common breast cancer risk prediction models, and those that have been done had small sample sizes and short follow-up periods, and used earlier versions of the prediction tools.